Just months after it started trading on the Nasdaq in June 2021, the company was valued as high as $5.8 billion. As of Friday, the firm’s shares were worth less than a dollar.

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' genetic information up for sale.

Following the firm’s bankruptcy, researchers hope that they will be able to continue accessing the valuable data set even if it is sold to new owners.

“Good Morning America” anchor Whit Johnson revealed that his 23andMe test was a “missing link” that led to a “bombshell” discovery for his family after the company filed for bankruptcy — sparking concerns about the personal data of its millions of customers.

The first clinical trial of a generative AI therapy bot suggests it was as effective as human therapy for people with depression, anxiety, or risk for developing eating disorders. Even so, it doesn’t give a go-ahead to the dozens of companies hyping such technologies while operating in a regulatory gray area. Read the full story.

Would you trust a company with your most personal data — your DNA — if it was on the brink of collapse? Millions of 23andMe customers are now facing that unsettling reality as the genetic testing company faces an uncertain future.

The company, which went public in 2021 with a $6 billion valuation, has never turned a profit and faced challenges including a data breach and a class-action lawsuit. 23andMe plans to sell ...

The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.